Interpretable neural network for risk stratification and drug target discovery based on PBMC transcriptomes
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Peripheral blood mononuclear cells (PBMCs) play a central role in immune surveillance and disease pathogenesis and provide a minimally invasive source for molecular screening. Here, we developed ME-NET, an intrinsically interpretable deep learning framework for multi-disease screening and risk stratification from PBMC transcriptomic profiles. Using harmonized datasets from heterogeneous clinical backgrounds, ME-NET showed consistent performance and outperformed standard machine-learning baselines. By incorporating curated pathway priors in a pathway-informed layer, ME-NET connects predictions to pathway-level signals and contributing genes, enabling biologically grounded interpretation of disease-associated immune programs. Finally, integrating ME-NET-prioritized targets with drug-gene interaction resources identified candidate compounds for potential therapeutic repurposing. Collectively, these results support the use of interpretable deep learning on blood-derived transcriptomes for scalable multi-disease screening and for prioritizing biomarkers and drug targets.
Fields of Study & Subjects
Bioinformatics and Genomic Networks
Computational Drug Discovery Methods
Gene expression and cancer classification
Publication details
- Journal / source
- iScience
- Volume
- 29
- Issue
- 4
- Pages
- 115538–115538
- Publication date
- 30 March 2026
- Language
- EN